U.S. Plasma Fractionation Market Size, Trends, Growth, Opportunities (2024-2032) | Grifols, S.A., CSL, and Octapharma AG

The U.S. plasma fractionation market size was worth USD 15.64 billion in 2022 and is projected to grow at a CAGR of 7.5% during the forecast period.

The U.S. plasma fractionation market continues to expand rapidly, driven by technological advancements, an increasing prevalence of immune disorders, and a growing demand for plasma-derived therapies. Companies in the sector are focused on innovation and improving accessibility to life-saving treatments, ensuring steady market growth.

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂'𝗿𝗲 𝗠𝗶𝘀𝘀𝗶𝗻𝗴: 𝗚𝗲𝘁 𝗮 𝗙𝗿𝗲𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗣𝗗𝗙) 𝗦𝗮𝗺𝗽𝗹𝗲: https://www.fortunebusinessinsights.com/enquiry/sample/u-s-plasma-fractionation-market-108476

𝗞𝗲𝘆 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁

In April 2023, CSL Behring received U.S. FDA clearance for Hizentra, a prefilled syringe of subcutaneous immunoglobulin (Human). This product is intended to treat Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Hizentra offers a more convenient option for patients, reinforcing CSL Behring's commitment to enhancing the quality of care for individuals with complex immune-related disorders.

𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. 𝗣𝗹𝗮𝘀𝗺𝗮 𝗙𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝘁𝗶𝗼𝗻 𝗠𝗮𝗿𝗸𝗲𝘁

Key players in the U.S. plasma fractionation market include:

• CSL (Australia)
• Grifols, S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Kedrion S.p.A (Italy)
• Octapharma AG (Switzerland)
• Bio Products Laboratory Ltd. (U.K.)
• LFB (France)
These companies are spearheading innovations in plasma fractionation, ensuring access to effective therapies for rare and chronic conditions.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀

𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴 𝗣𝗿𝗲𝘃𝗮𝗹𝗲𝗻𝗰𝗲 𝗼𝗳 𝗜𝗺𝗺𝘂𝗻𝗲 𝗗𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀

The growing incidence of immune deficiency diseases, such as Primary Immunodeficiency (PI) and autoimmune disorders, drives demand for plasma-derived therapies. These conditions necessitate consistent and effective treatments, making plasma fractionation a critical healthcare solution.

𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗣𝗹𝗮𝘀𝗺𝗮 𝗙𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝘁𝗶𝗼𝗻 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆

Technological advancements have revolutionized plasma fractionation, enabling the production of higher-purity plasma derivatives. Innovations have streamlined processes, reduced wastage, and improved the scalability of production, fostering market growth.

𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗗𝗲𝗺𝗮𝗻𝗱 𝗳𝗼𝗿 𝗜𝗺𝗺𝘂𝗻𝗼𝗴𝗹𝗼𝗯𝘂𝗹𝗶𝗻

The rising use of immunoglobulin for the treatment of neurological disorders, autoimmune diseases, and other immune-related conditions has significantly contributed to the market's expansion. With increasing clinical applications, immunoglobulin remains a cornerstone of plasma fractionation.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀

𝗦𝘂𝗽𝗽𝗹𝘆 𝗖𝗵𝗮𝗶𝗻 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀

The plasma fractionation process is heavily reliant on the availability of plasma donations, creating a supply chain bottleneck. This can limit production capacity and affect the timely delivery of treatments.

𝗛𝗶𝗴𝗵 𝗖𝗼𝘀𝘁 𝗼𝗳 𝗣𝗹𝗮𝘀𝗺𝗮-𝗗𝗲𝗿𝗶𝘃𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀

Plasma-derived products are costly due to the complexity of the fractionation process and stringent regulatory requirements. This poses affordability challenges for some patients, potentially restraining market growth.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲

A detailed market analysis covers growth trends, competitive landscapes, product segmentation, and emerging opportunities. Stakeholders can gain a comprehensive understanding of the market dynamics, empowering strategic decision-making.

𝗙𝗼𝗿 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 𝗩𝗶𝘀𝗶𝘁: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/u-s-plasma-fractionation-market-108476

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲

The U.S. plasma fractionation market is highly competitive, with companies focusing on innovation, geographic expansion, and strategic partnerships. For instance, CSL Behring, Grifols, and Takeda Pharmaceutical invest heavily in R&D to maintain their competitive edge. Emerging players are also contributing by addressing niche therapeutic needs, ensuring a dynamic market environment.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀

𝗜𝗺𝗺𝘂𝗻𝗼𝗴𝗹𝗼𝗯𝘂𝗹𝗶𝗻 𝗗𝗼𝗺𝗶𝗻𝗮𝘁𝗲𝘀 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁

By product, immunoglobulin accounts for a significant share of the plasma fractionation market. The wide-ranging applications of immunoglobulin in treating immune deficiencies and neurological disorders drive its dominance.

Other plasma-derived products, including albumin and coagulation factors, also play critical roles in addressing various medical needs, contributing to the market's diverse product portfolio.

𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀

The U.S. plasma fractionation market showcases robust growth across regions, driven by advancements in healthcare infrastructure and high patient awareness:

𝗡𝗼𝗿𝘁𝗵𝗲𝗮𝘀𝘁

The Northeast region leads in the adoption of plasma-derived therapies, supported by a strong network of healthcare providers and research institutions.

𝗠𝗶𝗱𝘄𝗲𝘀𝘁

The Midwest region has witnessed a rise in plasma donation centers, enabling steady supply chains and increased access to fractionation therapies.

𝗦𝗼𝘂𝘁𝗵

In the Southern U.S., increasing investments in healthcare facilities and growing awareness of plasma donation have bolstered regional market growth.

𝗪𝗲𝘀𝘁

The West Coast is a hub for innovation in plasma fractionation, driven by biotechnology firms and strong research collaborations.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲

The U.S. plasma fractionation market is poised for continued growth, with promising advancements and expanding therapeutic applications. Key trends shaping the future of the market include:

• 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗼𝗳 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Plasma-derived therapies are being explored for new medical indications, including Alzheimer's disease and cardiovascular disorders, paving the way for future growth.
• 𝗙𝗼𝗰𝘂𝘀 𝗼𝗻 𝗦𝗲𝗹𝗳-𝗔𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Products like CSL Behring's Hizentra exemplify the shift toward patient-centric solutions, emphasizing convenience and independence.
• 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗔𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀: Advances in recombinant DNA technology and synthetic biology may complement traditional plasma fractionation, enhancing treatment accessibility.
• 𝗚𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗦𝗲𝗰𝘁𝗼𝗿 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀: Increased funding for plasma donation programs and fractionation facilities will strengthen supply chains and foster market sustainability.
• 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗔𝗱𝘃𝗼𝗰𝗮𝗰𝘆 𝗮𝗻𝗱 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗖𝗮𝗺𝗽𝗮𝗶𝗴𝗻𝘀: Initiatives aimed at increasing plasma donation awareness will be critical for maintaining a steady supply of raw material for fractionation.

𝗖𝗼𝗻𝗰𝗹𝘂𝘀𝗶𝗼𝗻

The U.S. plasma fractionation market plays a pivotal role in addressing critical healthcare needs through innovative plasma-derived therapies. The FDA approval of CSL Behring's Hizentra exemplifies the industry's commitment to improving patient outcomes with advanced, patient-friendly solutions.

As leading companies like CSL, Grifols, and Takeda Pharmaceutical continue to invest in R&D and expand their product offerings, the market's future remains promising. For a detailed analysis of market trends, competitive dynamics, and growth prospects, explore the U.S. Plasma Fractionation Market Report.

𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗔𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗧𝗼 𝗬𝗼𝘂𝗿 𝗖𝗼𝗻𝘃𝗲𝗻𝗶𝗲𝗻𝗰𝗲: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/u-s-plasma-fractionation-market-108476

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.:+1 833 909 2966 (Toll-Free)
U.K.: +44 808 502 0280 (Toll-Free)
APAC +91 744 740 1245
Email: sales@fortunebusinessinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

This release was published on openPR.